These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24694642)

  • 1. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
    Hall JA; Salgado R; Lively T; Sweep F; Schuh A
    Lancet Oncol; 2014 Apr; 15(4):e184-93. PubMed ID: 24694642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk management approach for imaging biomarker-driven clinical trials in oncology.
    Liu Y; deSouza NM; Shankar LK; Kauczor HU; Trattnig S; Collette S; Chiti A
    Lancet Oncol; 2015 Dec; 16(16):e622-8. PubMed ID: 26678215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a checklist of quality indicators for clinical trials in resource-limited countries: the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience.
    Hanna M; Minga A; Fao P; Borand L; Diouf A; Mben JM; Gad RR; Anglaret X; Bazin B; Chene G;
    Clin Trials; 2013 Apr; 10(2):300-18. PubMed ID: 23345311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leaders worry that U.S. is losing edge on cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2008 Sep; 100(17):1196-9. PubMed ID: 18728275
    [No Abstract]   [Full Text] [Related]  

  • 10. A national cancer clinical trials system for targeted therapies.
    Mendelsohn J
    Sci Transl Med; 2011 Mar; 3(75):75cm8. PubMed ID: 21430266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical perspectives of personalized healthcare in oncology.
    Hodgson DR; Wellings R; Harbron C
    N Biotechnol; 2012 Sep; 29(6):656-64. PubMed ID: 22426411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early warning: an ailing canary in the mine.
    Dilts DM
    J Clin Oncol; 2010 Aug; 28(24):3799-800. PubMed ID: 20644096
    [No Abstract]   [Full Text] [Related]  

  • 13. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for the use of omics-based predictors in clinical trials.
    McShane LM; Cavenagh MM; Lively TG; Eberhard DA; Bigbee WL; Williams PM; Mesirov JP; Polley MY; Kim KY; Tricoli JV; Taylor JM; Shuman DJ; Simon RM; Doroshow JH; Conley BA
    Nature; 2013 Oct; 502(7471):317-20. PubMed ID: 24132288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and symptom management research sponsored by the National Cancer Institute.
    Minasian LM; O'Mara AM; Reeve BB; Denicoff AM; Kelaghan J; Rowland JH; Trimble EL;
    J Clin Oncol; 2007 Nov; 25(32):5128-32. PubMed ID: 17991932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
    J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Researchers left to guess at outcomes of most cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.